Every Sunday I write this newsletter with one mission: to empower longevity physicians.
This week I’m particularly excited to announce another layer of our ecosystem: research.
Our path has been deliberate: Community → Events → Education → Research.
Each step builds the infrastructure to democratize longevity medicine and make it the new standard of care.
Today we’re launching longevity docs.research
This is the first physician-powered Clinical Trial Network in longevity medicine.
First up: helping Mount Sinai recruit physician investigators for their XPRIZE Healthspan 2025 trial testing Rapamycin, Metformin, GLP-1s, and Spermidine with validated endpoints.
Healthy Sunday!
Dr. David Luu - Founder, longevity docs.™
PS: I designed this cover, inspired by the beauty and complexity of human connectivity, a reminder that every pathway in the body, like in longevity medicine, belongs to a larger system working in harmony.
Why we are launching the first Longevity Clinical Trial Network Powered by Physicians
Longevity medicine is emerging fast. Yet as the field grows, so does the need for validation.
Today, most interventions are supported by small studies, animal data, or anecdotal success.
Randomized clinical trials, while essential, remain costly, slow, and limited by infrastructure.
Traditional health systems aren’t designed for longevity research: too few investigators, too few patients, too many barriers between innovation and evidence.
That’s why we’re launching longevity docs.research the first Clinical Trial Network in longevity medicine, powered by physicians. Our mission: bring more evidence to the field and make longevity medicine the new standard of care.
With 600+ physicians worldwide already practicing longevity medicine, we’re uniquely positioned to bridge science, practice, and community. longevity docs.research connects physicians, academia, and innovators to create a new model: decentralized, data-driven, and clinically grounded.
Our first step: partner with academic institutions to help recruit principal investigators and patients for ongoing studies. Next, we’ll collaborate with innovators, from biotech to diagnostics, supplements, and wearable tech, to validate their interventions in real-world settings. Over time, we’ll empower physicians to run their own studies, contribute to longitudinal registries, and build an ever-growing base of real-world evidence.
We believe this model can redefine how research is conducted in longevity medicine: faster, more inclusive, and closer to the patients it’s meant to serve.
We’re starting by helping Mount Sinai recruit physician investigators for their XPRIZE Healthspan 2025 trial, testing Rapamycin, Metformin, GLP-1s, and Spermidine with validated healthspan endpoints.
Mount Sinai XPRIZE 2025 Healthspan Clinical Trial
Mount Sinai invites Principal Investigators to participate in the upcoming XPRIZE Healthspan 2025 clinical trial, a landmark initiative to quantify and optimize biological aging through immune, muscle, and cognitive outcomes.
Objective
To characterize the immunodynamic effects of widely used longevity interventions, including Spermidine, Rapamycin, Metformin, and GLP-1 agonists.
The study will generate real-world evidence on how these interventions modulate aging trajectories, while accelerating the transition from anecdote to evidence in longevity medicine.
Primary Outcomes
Validated Healthspan Improvement defined by personalized response thresholds across three key systems:
- Muscle Function: endurance capacity ( peak VO₂ ), lower body power, muscle mass ( D₃-creatine dilution )
- Cognitive Function: executive function, processing speed, working memory
- Immune Function: ex vivo naïve immune response to novel stimuli, immune cell composition ( IMM-AGE signature )
5 Reasons to Become a Physician Investigator
- Pioneer evidence-based longevity medicine to help establish the protocols that will define the field
- Offer your patients research-grade interventions with institutional backing
- Build academic credibility through publications and contribute to the scientific foundation of longevity care
- Get compensated for your participation: both PI fees and patient enrollment incentives provided
- Minimal time commitment: academic partners handle IRB, biomarker analytics, and infrastructure
Originally published in The Longevity Medicine Intelligence newsletter (Issue 70).
